Contusugene Ladenovec Gendux: Withdrawal of the marketing authorisation application


On 12 June 2009, Gendux Molecular Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Contusugene Ladenovec Gendux for the treatment of recurrent or refractory squamous cell carcinoma of the head and neck.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for Contusugene Ladenovec Gendux (contusugene ladenovec) (PDF/43.18 KB)

    First published: 23/07/2009
    Last updated: 23/07/2009

  • Key facts

    Contusugene Ladenovec Gendux
    Product number
    Date of withdrawal
    Company making the application
    Gendux Molecular Limited
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating